KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Net Income towards Common Stockholders (2016 - 2026)

Neogenomics filings provide 17 years of Net Income towards Common Stockholders readings, the most recent being -$17.1 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 34.01% to -$17.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$99.2 million, a 27.87% decrease, with the full-year FY2025 number at -$108.0 million, down 37.22% from a year prior.
  • Net Income towards Common Stockholders hit -$17.1 million in Q1 2026 for Neogenomics, down from -$9.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$9.9 million in Q4 2025 to a low of -$49.4 million in Q1 2022.
  • Median Net Income towards Common Stockholders over the past 5 years was -$24.3 million (2023), compared with a mean of -$25.7 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 146.53% in 2022 and later surged 49.76% in 2023.
  • Neogenomics' Net Income towards Common Stockholders stood at -$22.7 million in 2022, then soared by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then surged by 35.52% to -$9.9 million in 2025, then crashed by 73.12% to -$17.1 million in 2026.
  • The last three reported values for Net Income towards Common Stockholders were -$17.1 million (Q1 2026), -$9.9 million (Q4 2025), and -$27.1 million (Q3 2025) per Business Quant data.